FDA official discusses agency’s new Rare Disease Innovation Hub
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyCBERCDEROrphan drugsProduct LifecycleUnited StatesUS Food and Drug Administration (FDA)Regulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesBiotechnologyCBERCDEROrphan drugsProduct LifecycleUnited StatesUS Food and Drug Administration (FDA)